Phase 2 Completed N=82 Randomized Triple-blind Treatment

Exenatide Once Weekly for Smoking Cessation

Source: ClinicalTrials.gov NCT02975297 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2021

Primary outcomePrimary: Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppm — 19; 11 Participants

Summary

The purpose of this study is to identify a potential new treatment for smoking cessation.

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppm	9; 4	—
PRIMARY Post-quit Craving as Assessed by the Questionnaire of Smoking Urges	11.5; 11.2	—
PRIMARY Withdrawal Symptoms as Assessed by the Wisconsin Smoking Withdrawal Scale	40.5; 44.5	—
PRIMARY Cue-induced Craving for Cigarettes Following Virtual Reality Exposure as Assessed by the Questionnaire of Smoking Urges	—	—
PRIMARY Cue-induced Craving for Cigarettes Following Virtual Reality Exposure as Assessed by the Questionnaire of Smoking Urges	—	—
SECONDARY Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppm	9; 4	—
SECONDARY Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppm	9; 4	—
SECONDARY Post-quit Craving as Assessed by the Questionnaire of Smoking Urges	11.5; 11.2	—
SECONDARY Post-quit Craving as Assessed by the Questionnaire of Smoking Urges	11.5; 11.2	—

Eligibility Criteria

Inclusion Criteria

Be English-speaking volunteers who desire to quit smoking and are willing to make a quit attempt during the course of the study;
Have smoked ≥10 cigarettes a day for at least one year and provide a breath carbon monoxide (CO) ≥10 ppm;
Have a negative pregnancy test, if female of childbearing potential;
Have HbA1C levels between 5.7 and 6.4% or BMI of or greater than 25 kg/square meters
Not currently using any therapy for glycemic control (either injectable [i.e. insulin] or oral agents);
Have vital signs as follows: resting pulse between 50 and 95 bpm, BP between 90-150 mmHg systolic and 45-95 mmHg diastolic;
Have hematology and chemistry laboratory tests that are within reference limits (within 10% above or below), with the following exception: pancreatic tests (lipase and amylase) must be within normal limits;
Have a medical history and brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the principal investigator.

Exclusion Criteria

Meet criteria for the following psychiatric and/or substance use disorders as assessed by the Mini International Neuropsychiatric Interview (MINI): items C (current manic or hypomanic episode only), I (alcohol abuse - Alcohol Addendum-past 3 months only; current alcohol dependence), J (substance abuse -Substance Abuse Addendum - past 3 months only; current substance dependence), K (current psychotic disorder or current mood disorder with psychotic features).
Individuals who meet criteria for non-exclusionary psychiatric disorders that are considered clinically unstable and/or unsuitable to participate as determined by the Principal Investigator and/or Study Physician.
Individuals rated as moderate (9-16) to high (17 or greater) on suicidality as assessed by Module B of the MINI.
Have personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2;
Have type 1 diabetes mellitus;
Have severe cardiovascular disease (history of myocardial infarction, life-threatening arrhythmia, or worsening angina pectoris);
Have active temporomandibular joint disease;
Have severe gastrointestinal disease (i.e. severe gastroparesis);
Have previous history of pancreatitis or are at risk for pancreatitis;
Have creatinine clearance (CrCl) < 30;
Have any previous medically adverse reaction to study medications, nicotine, or menthol;
Be pregnant or lactating or unwilling to provide a negative pregnancy test before study entry;
Not using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or spermicide);
Have any illness which in the opinion of the primary investigator would preclude safe and/or successful completion of the study.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02975297). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.